New directions in cellular therapy of cancer: A summary of the summit on cellular therapy for cancer

David F. Stroncek, Carolina Berger, Martin A. Cheever, Richard W. Childs, Mark E. Dudley, Peter Flynn, Luca Gattinoni, James R. Heath, Michael Kalos, Francesco M. Marincola, Jeffrey S. Miller, Gustavo Mostoslavsky, Daniel J. Powell, Mahendra Rao, Nicholas P. Restifo, Steven A. Rosenberg, John O'Shea, Cornelis J M Melief

Research output: Contribution to journalArticle

Abstract

A summit on cellular therapy for cancer discussed and presented advances related to the use of adoptive cellular therapy for melanoma and other cancers. The summit revealed that this field is advancing rapidly. Conventional cellular therapies, such as tumor infiltrating lymphocytes (TIL), are becoming more effective and more available. Gene therapy is becoming an important tool in adoptive cell therapy. Lymphocytes are being engineered to express high affinity T cell receptors (TCRs), chimeric antibody-T cell receptors (CARs) and cytokines. T cell subsets with more naïve and stem cell-like characteristics have been shown in pre-clinical models to be more effective than unselected populations and it is now possible to reprogram T cells and to produce T cells with stem cell characteristics. In the future, combinations of adoptive transfer of T cells and specific vaccination against the cognate antigen can be envisaged to further enhance the effectiveness of these therapies.

Original languageEnglish (US)
Article number48
JournalJournal of Translational Medicine
Volume10
Issue number1
DOIs
StatePublished - Mar 15 2012
Externally publishedYes

Fingerprint

T-cells
Lymphocytes
Stem cells
T-Lymphocytes
Neoplasms
Stem Cells
Tumor-Infiltrating Lymphocytes
Gene therapy
Adoptive Transfer
T-Lymphocyte Subsets
Therapeutics
Cell- and Tissue-Based Therapy
T-Cell Antigen Receptor
Genetic Therapy
Tumors
Melanoma
Vaccination
Antigens
Direction compound
Antibodies

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Stroncek, D. F., Berger, C., Cheever, M. A., Childs, R. W., Dudley, M. E., Flynn, P., ... Melief, C. J. M. (2012). New directions in cellular therapy of cancer: A summary of the summit on cellular therapy for cancer. Journal of Translational Medicine, 10(1), [48]. https://doi.org/10.1186/1479-5876-10-48

New directions in cellular therapy of cancer : A summary of the summit on cellular therapy for cancer. / Stroncek, David F.; Berger, Carolina; Cheever, Martin A.; Childs, Richard W.; Dudley, Mark E.; Flynn, Peter; Gattinoni, Luca; Heath, James R.; Kalos, Michael; Marincola, Francesco M.; Miller, Jeffrey S.; Mostoslavsky, Gustavo; Powell, Daniel J.; Rao, Mahendra; Restifo, Nicholas P.; Rosenberg, Steven A.; O'Shea, John; Melief, Cornelis J M.

In: Journal of Translational Medicine, Vol. 10, No. 1, 48, 15.03.2012.

Research output: Contribution to journalArticle

Stroncek, DF, Berger, C, Cheever, MA, Childs, RW, Dudley, ME, Flynn, P, Gattinoni, L, Heath, JR, Kalos, M, Marincola, FM, Miller, JS, Mostoslavsky, G, Powell, DJ, Rao, M, Restifo, NP, Rosenberg, SA, O'Shea, J & Melief, CJM 2012, 'New directions in cellular therapy of cancer: A summary of the summit on cellular therapy for cancer', Journal of Translational Medicine, vol. 10, no. 1, 48. https://doi.org/10.1186/1479-5876-10-48
Stroncek, David F. ; Berger, Carolina ; Cheever, Martin A. ; Childs, Richard W. ; Dudley, Mark E. ; Flynn, Peter ; Gattinoni, Luca ; Heath, James R. ; Kalos, Michael ; Marincola, Francesco M. ; Miller, Jeffrey S. ; Mostoslavsky, Gustavo ; Powell, Daniel J. ; Rao, Mahendra ; Restifo, Nicholas P. ; Rosenberg, Steven A. ; O'Shea, John ; Melief, Cornelis J M. / New directions in cellular therapy of cancer : A summary of the summit on cellular therapy for cancer. In: Journal of Translational Medicine. 2012 ; Vol. 10, No. 1.
@article{07fe194e2196473fab8f0c4a91a7155a,
title = "New directions in cellular therapy of cancer: A summary of the summit on cellular therapy for cancer",
abstract = "A summit on cellular therapy for cancer discussed and presented advances related to the use of adoptive cellular therapy for melanoma and other cancers. The summit revealed that this field is advancing rapidly. Conventional cellular therapies, such as tumor infiltrating lymphocytes (TIL), are becoming more effective and more available. Gene therapy is becoming an important tool in adoptive cell therapy. Lymphocytes are being engineered to express high affinity T cell receptors (TCRs), chimeric antibody-T cell receptors (CARs) and cytokines. T cell subsets with more na{\"i}ve and stem cell-like characteristics have been shown in pre-clinical models to be more effective than unselected populations and it is now possible to reprogram T cells and to produce T cells with stem cell characteristics. In the future, combinations of adoptive transfer of T cells and specific vaccination against the cognate antigen can be envisaged to further enhance the effectiveness of these therapies.",
author = "Stroncek, {David F.} and Carolina Berger and Cheever, {Martin A.} and Childs, {Richard W.} and Dudley, {Mark E.} and Peter Flynn and Luca Gattinoni and Heath, {James R.} and Michael Kalos and Marincola, {Francesco M.} and Miller, {Jeffrey S.} and Gustavo Mostoslavsky and Powell, {Daniel J.} and Mahendra Rao and Restifo, {Nicholas P.} and Rosenberg, {Steven A.} and John O'Shea and Melief, {Cornelis J M}",
year = "2012",
month = "3",
day = "15",
doi = "10.1186/1479-5876-10-48",
language = "English (US)",
volume = "10",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - New directions in cellular therapy of cancer

T2 - A summary of the summit on cellular therapy for cancer

AU - Stroncek, David F.

AU - Berger, Carolina

AU - Cheever, Martin A.

AU - Childs, Richard W.

AU - Dudley, Mark E.

AU - Flynn, Peter

AU - Gattinoni, Luca

AU - Heath, James R.

AU - Kalos, Michael

AU - Marincola, Francesco M.

AU - Miller, Jeffrey S.

AU - Mostoslavsky, Gustavo

AU - Powell, Daniel J.

AU - Rao, Mahendra

AU - Restifo, Nicholas P.

AU - Rosenberg, Steven A.

AU - O'Shea, John

AU - Melief, Cornelis J M

PY - 2012/3/15

Y1 - 2012/3/15

N2 - A summit on cellular therapy for cancer discussed and presented advances related to the use of adoptive cellular therapy for melanoma and other cancers. The summit revealed that this field is advancing rapidly. Conventional cellular therapies, such as tumor infiltrating lymphocytes (TIL), are becoming more effective and more available. Gene therapy is becoming an important tool in adoptive cell therapy. Lymphocytes are being engineered to express high affinity T cell receptors (TCRs), chimeric antibody-T cell receptors (CARs) and cytokines. T cell subsets with more naïve and stem cell-like characteristics have been shown in pre-clinical models to be more effective than unselected populations and it is now possible to reprogram T cells and to produce T cells with stem cell characteristics. In the future, combinations of adoptive transfer of T cells and specific vaccination against the cognate antigen can be envisaged to further enhance the effectiveness of these therapies.

AB - A summit on cellular therapy for cancer discussed and presented advances related to the use of adoptive cellular therapy for melanoma and other cancers. The summit revealed that this field is advancing rapidly. Conventional cellular therapies, such as tumor infiltrating lymphocytes (TIL), are becoming more effective and more available. Gene therapy is becoming an important tool in adoptive cell therapy. Lymphocytes are being engineered to express high affinity T cell receptors (TCRs), chimeric antibody-T cell receptors (CARs) and cytokines. T cell subsets with more naïve and stem cell-like characteristics have been shown in pre-clinical models to be more effective than unselected populations and it is now possible to reprogram T cells and to produce T cells with stem cell characteristics. In the future, combinations of adoptive transfer of T cells and specific vaccination against the cognate antigen can be envisaged to further enhance the effectiveness of these therapies.

UR - http://www.scopus.com/inward/record.url?scp=84862805383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862805383&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-10-48

DO - 10.1186/1479-5876-10-48

M3 - Article

C2 - 22420641

AN - SCOPUS:84862805383

VL - 10

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 48

ER -